SomnoMed Ltd
Company Profile
- Business description- SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region. 
- Contact- 20 Clarke Street 
 Level 3
 Crows Nest
 SydneyNSW2065
 AUS- T: +61 294670400 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Medical Devices - Fiscal Year End- 30 June 2026 - Employees- 22 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,205.00 | 1.70 | -0.02% | 
| CAC 40 | 8,157.29 | 43.59 | -0.53% | 
| DAX 40 | 24,118.89 | 5.32 | -0.02% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,760.06 | 3.92 | 0.04% | 
| HKSE | 26,050.08 | 232.61 | -0.89% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 52,211.69 | 886.08 | 1.73% | 
| NZX 50 Index | 13,544.51 | 85.22 | 0.63% | 
| S&P 500 | 6,822.34 | 68.25 | -0.99% | 
| S&P/ASX 200 | 8,909.10 | 4.10 | -0.05% | 
| SSE Composite Index | 3,961.62 | 25.28 | -0.63% |